JIM CRAMERNew Market: Cramer's 'Mad Money' Recap (Thursday 5/28/20)By Scott RuttMay 28, 2020 8:58 PM EDT
JIM CRAMERNew Market: Cramer's 'Mad Money' Recap (Thursday 5/28/20)By Scott RuttMay 28, 2020 8:58 PM EDT
PRESS RELEASESTeva Announces Virtual 2020 Annual Meeting Of ShareholdersBy Business WireMay 26, 2020 8:00 AM EDT
PRESS RELEASESTeva To Present New AJOVY® (fremanezumab) Analyses And Latest COPAXONE® Data (glatiramer Acetate Injection) At European Academy Of Neurology CongressBy Business WireMay 22, 2020 2:00 AM EDT
PRESS RELEASESChina Approves AUSTEDO® For Treating Chorea Associated With Huntington's Disease And Tardive Dyskinesia In AdultsBy Business WireMay 18, 2020 7:00 AM EDT
INVESTINGBuffett Exits Phillips 66 and Travelers, Trims Goldman SachsBy Tom BemisMay 15, 2020 7:37 PM EDT
INVESTINGTeva Soars as Generic Drugmaker Tops Earnings and Revenue EstimatesBy Scott Van VoorhisMay 7, 2020 9:07 AM EDT
PRESS RELEASESNew Data For Teva AJOVY® (fremanezumab-vfrm) Injection And AUSTEDO® (deutetrabenazine) Tablets Included In NeurologyBy Business WireMay 1, 2020 8:00 AM EDT
PRESS RELEASESTeva To Host Conference Call To Discuss First Quarter 2020 Financial Results At 8 A.m. ET On May 7, 2020By Business WireApr 16, 2020 6:27 PM EDT
HEALTHCoronavirus Latest Updates: A Timeline of Recent EventsBy Steve FiorilloMar 30, 2020 12:05 PM EDT
INVESTINGTeva Donates 6 Million Tablets of Malaria Drug to Fight Coronavirus in U.S.By Dan WeilMar 20, 2020 10:44 AM EDT
PRESS RELEASESTeva To Donate Potential COVID-19 Treatment, Hydroxychloroquine Sulfate Tablets To Hospitals NationwideBy Business WireMar 19, 2020 8:23 PM EDT
PRESS RELEASESPositive Recommendation By NICE For First Anti-CGRP Migraine Therapy: AJOVY®▼ (fremanezumab)By Business WireMar 12, 2020 3:30 AM EDT
PRESS RELEASESTeva Announces FDA Approval Of ArmonAir® Digihaler™ (fluticasone Propionate) Inhalation PowderBy Business WireFeb 24, 2020 8:00 AM EST
PRESS RELEASESTeva Announces Registration Trials Of Deutetrabenazine In Pediatric Patients With Tourette Syndrome Did Not Meet The Primary EndpointBy Business WireFeb 19, 2020 4:05 PM EST
INVESTINGWarren Buffett’s Berkshire Hathaway Takes Stakes in Kroger, Biogen; Cuts Banks and AppleBy Tom BemisFeb 14, 2020 7:58 PM EST
INVESTINGTeva Pharmaceutical Jumps After Earnings Meet Wall Street EstimatesBy M. Corey GoldmanFeb 12, 2020 9:41 AM EST
MARKETSBernie Sanders, Coronavirus, Cisco, CVS and Lyft - 5 Things You Must Know WednesdayBy Joseph WoelfelFeb 12, 2020 6:52 AM EST
PRESS RELEASESTeva Announces Positive Top-Line Results From AJOVY® (fremanezumab) Clinical Trials In JapanBy Business WireFeb 3, 2020 3:30 AM EST
PRESS RELEASESTeva Announces FDA Approval Of AJOVY® (fremanezumab-vfrm) Injection AutoinjectorBy Business WireJan 28, 2020 4:05 PM EST
PRESS RELEASESTeva To Host Conference Call To Discuss Fourth Quarter 2019 Financial Results And 2020 Financial Guidance At 8 A.m. ET On February 12, 2020By Business WireJan 15, 2020 5:00 PM EST
STOCKSOpioid Companies Face U.S. Criminal Inquiry Under Drug-Dealing Law: ReportBy Rob DanielNov 26, 2019 1:59 PM EST
STOCKSTeva, Generic Drugmakers Reportedly Aiming to Settle U.S. Antitrust InquiryBy Rob DanielNov 25, 2019 11:06 AM EST
